- Home
- CCSI vs AVIR Comparison
CCSI vs AVIR Comparison
Compare CCSI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCSI | AVIR |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.4M | 450.9M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCSI | AVIR |
|---|---|---|
| Price | $26.40 | $5.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $37.50 | $8.00 |
| AVG Volume (30 Days) | 107.2K | ★ 375.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 4.35 | N/A |
| Revenue | $349,696,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.84 | $2.46 |
| 52 Week High | $31.67 | $6.45 |
Technical Indicators
Market Signals| Indicator | CCSI | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 52.84 |
| Support Level | $25.07 | $3.28 |
| Resistance Level | $26.62 | $6.37 |
| Average True Range (ATR) | 1.04 | 0.25 |
| MACD | 0.21 | -0.03 |
| Stochastic Oscillator | 94.63 | 51.94 |
Price Performance
Historical ComparisonAbout CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.